Physician profile
Frederick J Pope
NPI 1912984618
$5,251.20
in general payments reported to CMS, 2019-2025
42 companies · $25.45 in 2025
The $25.45 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,913 · 2020: $1,001 · 2021: $1,413 · 2022: $899 · 2025: $25.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $25.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $25.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $715.44 | 2021-2022 | |
| Pfizer INC. | $675.61 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $433.60 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $423.40 | 2019-2022 | |
| Alkermes, INC. | $334.29 | 2019-2022 | |
| Allergan, INC. | $281.06 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.61 | 2019-2022 | |
| Amarin Pharma, INC. | $193.34 | 2019-2021 | |
| Astellas Pharma US INC | $187.14 | 2019-2022 | |
| Amgen INC. | $162.34 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $161.63 | 2019-2022 | |
| Novo Nordisk INC | $155.99 | 2019-2022 | |
| Lilly USA, LLC | $123.65 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.25 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.34 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Pope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.